NCT03653741View on ClinicalTrials.gov

Effects of Perampanel on Neurophysiology Test Perimeters

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions
Healthy
Interventions
DRUG

Perampanel 6 MG

Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.

Trial Locations (1)

10021

Neurophysiology Laboratory, New York

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT03653741 - Effects of Perampanel on Neurophysiology Test Perimeters | Biotech Hunter | Biotech Hunter